E3 PreliminaryPreliminaryPEM requiredObservationalPeer-reviewedReviewed
Atopy and Elevation of IgE, IgG3, and IgG4 May Be Risk Factors for Post COVID-19 Condition in Children and Adolescents.
Körner, Robert Walter, Bansemir, Ole Yannick, Franke, Rosa et al. · Children (Basel, Switzerland) · 2023 · DOI
Quick Summary
This study examined 28 children and teens who developed long-lasting symptoms after COVID-19 infection. The researchers found that most patients had allergies and unusually high levels of immune proteins called IgE, IgG3, and IgG4. About three in ten patients also met criteria for ME/CFS, experiencing severe fatigue, breathing problems, and post-exertional malaise (feeling worse after activity). Most patients gradually improved over about a year, though some took longer to recover.
Why It Matters
This study provides evidence that specific immune dysregulation patterns—particularly elevated IgG3 and IgG4—may predispose children to develop ME/CFS as a complication of COVID-19. Understanding these immunological risk factors could help identify at-risk patients early and inform future therapeutic interventions targeting immune dysfunction in post-viral ME/CFS.
Observed Findings
- 93% of PCC patients had aeroallergen sensitizations
- Elevated IgE levels were found in patients regardless of initial COVID-19 disease severity (mean 174.2 kU/L vs reference < 100 kU/L)
- 29% of PCC patients met ME/CFS criteria
- Elevated IgG3 and IgG4 were significantly associated with ME/CFS diagnosis (p < 0.05)
- 57% of patients showed recovery within a mean of 12.7 months (range 5-25 months)
Inferred Conclusions
- Atopy and elevated IgE represent potential risk factors for pediatric post COVID-19 condition
- Immune dysregulation affecting IgG subclasses (IgG3 and IgG4) may specifically predispose to ME/CFS manifestation in post-COVID patients
- Pediatric PCC demonstrates heterogeneous recovery trajectories, with most patients achieving gradual improvement over 12-30 months
- Immune dysregulation rather than persistent viral replication may underlie the pathophysiology of PCC with concurrent ME/CFS
Remaining Questions
- Why do elevated IgG3 and IgG4 specifically increase ME/CFS risk in some post-COVID patients but not others?
- Does immune dysregulation precede symptom onset, or does it develop as a consequence of viral infection and persistent inflammation?
What This Study Does Not Prove
This observational study cannot establish causation or explain why certain immune patterns lead to ME/CFS development. The small sample size (n=28) and single-center design limit generalizability to broader pediatric populations. The study does not prove that elevated IgE, IgG3, or IgG4 directly cause PCC or ME/CFS, only that they correlate with these conditions.
Tags
Symptom:Post-Exertional MalaiseFatigueSensory Sensitivity
Biomarker:Blood Biomarker
Phenotype:Infection-TriggeredPediatricLong COVID Overlap
Method Flag:No ControlsSmall SampleExploratory OnlyWeak Case DefinitionMixed CohortPEM Not Defined
Metadata
- DOI
- 10.3390/children10101598
- PMID
- 37892261
- Review status
- Editor reviewed
- Evidence level
- Early hypothesis, preprint, editorial, or weak support
- Last updated
- 12 April 2026
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Contribute
Private, reviewed by a human. Not a public comment thread.